Navigation Links
Delcath to Present at the JMP Securities Healthcare Conference on September 28, 2011
Date:9/19/2011

NEW YORK, Sept. 19, 2011 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) announced today that management will present at the JMP Securities Healthcare Conference on Wednesday, September 28, 2011 at 11:00 A.M. ET in New York, NY.  David McDonald, Chief Financial Officer, will provide an overview of the Company's business strategy and recent corporate developments.

Attendance at this conference is by invitation only.  Delcath will offer a live webcast and subsequent archived replay of its presentation, which may be accessed at http://www.delcath.com/investors/events/.

About Delcath SystemsDelcath Systems, Inc. is a development stage specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi-arm Phase II trial to treat other liver cancers. The Company obtained authorization to affix a CE Mark for the Hepatic CHEMOSAT delivery system in April 2011. The Company has not yet received FDA approval for commercial sale of its system in the United States. For more information, please visit the Company's website at http://www.delcath.com/.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to di
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems Begins Data Analysis of Phase III Trial
11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015 Registration is officially open for MEDTEC China ... at the Shenzhen Convention & Exhibition Center. The ... to join the MEDTEC China family of events. MEDTEC China ... to better serve the South China ... an important region for China,s medical ...
(Date:3/3/2015)... Md. , March 3, 2015 /PRNewswire/-- ViaCyte, Inc., a ... islet replacement therapy for the treatment of diabetes in ... Eugene Brandon , Director of Strategic Relations and Project ... showcases the latest in type 1 diabetes management technology ... as follows: , , , Title:   , ...
(Date:3/3/2015)... and NEW YORK , March 3, ... ), a biopharmaceutical company advancing protein biologic therapies and ... at the 27 th Annual ROTH Capital Partners ... at The Ritz-Carlton, Laguna Niguel in Dana Point, California.  ... Wehner , is scheduled to present a corporate update ...
Breaking Medicine Technology:Pre-registration Open for 2015 MEDTEC China South 2Pre-registration Open for 2015 MEDTEC China South 3ViaCyte to Present at JDRF TypeOneNation Research Summit 2PlasmaTech Biopharmaceuticals To Present at 27th Annual ROTH Capital Partners Conference 2
... , WALTHAM, Mass., Nov. ... authority on medical technology market intelligence, policy changes made by ... a surge in obstructive sleep apnea (OSA) diagnostic testing and ... Sleep Management Devices 2010 report finds that increasing reimbursement ...
... Nov. 16 Epilepsy and seizures affect nearly 3 million Americans ... cause is apparent. Those who live daily with the condition have ... long it will last or where they will be, often experiencing ... The wonder behind the diagnosis, the perseverance in managing it, ...
Cached Medicine Technology:Sleep Management Device Unit Sales to Grow at a Compound Annual Growth Rate of Over 16% as CMS Reimbursement Expands 2Sleep Management Device Unit Sales to Grow at a Compound Annual Growth Rate of Over 16% as CMS Reimbursement Expands 3National Expressions of Courage Art Contest Unveils Stories of Inspiration 2National Expressions of Courage Art Contest Unveils Stories of Inspiration 3National Expressions of Courage Art Contest Unveils Stories of Inspiration 4National Expressions of Courage Art Contest Unveils Stories of Inspiration 5
(Date:3/3/2015)... Chicago, Il. (PRWEB) March 03, 2015 ... – is set to reveal the world’s first fully ... you are breathing and controls an air purifier to ... the user informed, and in control, via phone, tablet ... air purifiers in over 50 countries worldwide, will unveil ...
(Date:3/3/2015)... In March, 1% for the Planet ... off a new campaign, “Know Your Source,” which calls for ... ambassadors in their quest for ingredient awareness and better business ... its members and partners, including King Arthur Flour, Good Culture, ... raise awareness for food as an environmental issue, with a ...
(Date:3/3/2015)... US Air Purifiers LLC , an Illinois ... pleased to announce that all Rabbit brand air purifiers are ... the west coast port strikes. This news comes just in ... , The port strikes, which have caused significant ... economic growth by as much as 1%, have hindered the ...
(Date:3/3/2015)... March 03, 2015 Topical BioMedics, Inc., announces ... webinar streamed live on Tuesday, March 10th, 12pm – 1pm ... archived and accessible 24/7. , The Pain ... topic for the March 10th workshop is “Opioid Addiction: ... that the U.S. represents 5% of the world’s population, yet ...
(Date:3/3/2015)... The combinatorial, multi-gene GeneSight test ... outcomes for patients with depression, and their use ... individual genes that comprise the test, according to ... Clinic and Assurex Health, and published online by ... technology of the GeneSight Psychotropic test is based ...
Breaking Medicine News(10 mins):Health News:Smart sensor and air purifier interconnect to track and trap dust, pollen and dangerous particles in home and workplace air 2Health News:1% For the Planet Asks Consumers to “Know Your Source” 2Health News:Rabbit Air Purifiers Back In Stock at US Air Purifiers LLC 2Health News:Rabbit Air Purifiers Back In Stock at US Air Purifiers LLC 3Health News:Topical BioMedics Hosts March Pain Management Webinar 2Health News:Topical BioMedics Hosts March Pain Management Webinar 3Health News:Topical BioMedics Hosts March Pain Management Webinar 4Health News:Topical BioMedics Hosts March Pain Management Webinar 5Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 2Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 3Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 4Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 5Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 6
... ... Warady & Davis LLP, Certified Public Accountants & Consultants, as one of the ... University" training program, flexible scheduling, great team atmosphere built on friendships and many perks. ... Deerfield, IL ...
... Swedish researchers found that rheumatoid arthritis (RA) patients did ... 6 years after starting anti-tumor necrosis factor (TNF) therapy. ... Ph.D., from Karolinska University Hospital in Stockholm, Sweden assessed ... using anti-TNF therapies: infliximab, adalimumab, and etanercept. Details ...
... Realty Trust, Inc. (NYSE: BMR ), a real estate ... Science Industry®, today announced operating and financial results for the ... http://www.newscom.com/cgi-bin/prnh/20091005/BIOMEDLOGO ) , Highlights: , Increased total ... from $80.8 million for the same period in 2008. ...
... , WASHINGTON, Oct. 28 Trust for America,s ... a new ad campaign today entitled Health Care vs. ... reform provides a once-in-a-lifetime chance to transform our health care ... prevention and wellness," said Jeff Levi, PhD, Executive Director of ...
... ROCKVILLE, Md., Oct. 28 Vanda Pharmaceuticals Inc. (Vanda) ... the development and commercialization of clinical-stage product candidates for ... results for the quarter ended September 30, 2009, on ... full text copy of the release will be disseminated ...
... CSV ) today announced results for the third quarter ended September 30, 2009. Financial highlights from continuing operations for the third ... Results, (amounts in millions, except per share amounts), ... ... ...
Cached Medicine News:Health News:Warady & Davis LLP Named One of 'Top 50 Employers for Generation Y Chicago' 2Health News:Warady & Davis LLP Named One of 'Top 50 Employers for Generation Y Chicago' 3Health News:Anti-tumor necrosis factor treatment does not increase cancer Risk in RA patients 2Health News:BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 2Health News:BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 3Health News:BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 4Health News:BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 5Health News:BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 6Health News:BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 7Health News:BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 8Health News:BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 9Health News:BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 10Health News:BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 11Health News:BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 12Health News:BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 13Health News:BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 14Health News:BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 15Health News:New Health Care vs. Sick Care Ad Campaign Launched by Trust for America's Health and Partnership for Prevention 2Health News:New Health Care vs. Sick Care Ad Campaign Launched by Trust for America's Health and Partnership for Prevention 3Health News:Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009 2Health News:Carriage Services Announces Third Quarter 2009 Results 2Health News:Carriage Services Announces Third Quarter 2009 Results 3Health News:Carriage Services Announces Third Quarter 2009 Results 4Health News:Carriage Services Announces Third Quarter 2009 Results 5Health News:Carriage Services Announces Third Quarter 2009 Results 6Health News:Carriage Services Announces Third Quarter 2009 Results 7Health News:Carriage Services Announces Third Quarter 2009 Results 8Health News:Carriage Services Announces Third Quarter 2009 Results 9Health News:Carriage Services Announces Third Quarter 2009 Results 10Health News:Carriage Services Announces Third Quarter 2009 Results 11Health News:Carriage Services Announces Third Quarter 2009 Results 12Health News:Carriage Services Announces Third Quarter 2009 Results 13Health News:Carriage Services Announces Third Quarter 2009 Results 14Health News:Carriage Services Announces Third Quarter 2009 Results 15Health News:Carriage Services Announces Third Quarter 2009 Results 16
... Test is a clinical chemistry assay that ... the cobalt binding capacity of albumin in ... the early 1990s, IMA is produced when ... tissue in the heart. During ischemia, the ...
Inquire...
... autoimmune testing feature single-well ANA screen and ... reflex tests including dsDNA, and 6 individual ... (La), Scl-70 and Jo-1. In addition, our ... of products for Cardiolipins (IgA, IgG, IgM), ...
... a leading provider of immunofluorescence assays, with ... that includes kits for autoimmune diseases, infectious ... conjugates and components. Our Impact IFA Test ... substrates and kit sizes to choose from. ...
Medicine Products: